Khorasanizadeh MirHojjat, Eskian Mahsa, Assa'ad Amal H, Camargo Carlos A, Rezaei Nima
a Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences , Tehran , Iran.
b Division of Allergy and Immunology, Cincinnati Children's Medical Center , Cincinnati , Ohio , USA.
Int Rev Immunol. 2016 Jul 3;35(4):294-311. doi: 10.3109/08830185.2015.1128901. Epub 2016 Apr 27.
Nonresponders to maximal guideline-based therapies of asthma account for most of the morbidity, mortality, and economic burden of the disease. Because eosinophils are key effector cells in asthmatic airway inflammation, blocking IL-5, the main cytokine responsible for its survival and activation, seems to be a rational strategy. While previous monoclonal antibodies against the IL-5 ligand resulted in inconsistent improvements in asthma outcomes, benralizumab has shown promise. Benralizumab is a monoclonal antibody against IL-5 receptor, and has an enhanced antibody dependent cell-mediated cytotoxicity function. In this article, we review the theoretical advantages of benralizumab compared to previous compounds, as well as current status of the clinical development of benralizumab in asthma. Lastly, we briefly discuss the potential role of benralizumab in chronic obstructive pulmonary disease.
哮喘患者中，对基于指南的最大程度治疗无反应者占该疾病大部分的发病率、死亡率及经济负担。由于嗜酸性粒细胞是哮喘气道炎症中的关键效应细胞，阻断白细胞介素-5（IL-5）（负责其存活和激活的主要细胞因子）似乎是一种合理的策略。虽然先前针对IL-5配体的单克隆抗体在哮喘治疗效果上改善并不一致，但贝那利珠单抗已展现出前景。贝那利珠单抗是一种针对IL-5受体的单克隆抗体，具有增强的抗体依赖性细胞介导的细胞毒性功能。在本文中，我们回顾了贝那利珠单抗与先前化合物相比的理论优势，以及贝那利珠单抗在哮喘临床开发的现状。最后，我们简要讨论了贝那利珠单抗在慢性阻塞性肺疾病中的潜在作用。
